- Home
- LGI vs NYXH Comparison
LGI vs NYXH Comparison
Compare LGI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | NYXH |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 188.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGI | NYXH |
|---|---|---|
| Price | $18.04 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 41.1K | 37.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $12.66 | $4.35 |
| 52 Week High | $16.68 | $11.87 |
Technical Indicators
Market Signals| Indicator | LGI | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 65.45 | 59.98 |
| Support Level | $17.73 | $5.07 |
| Resistance Level | $18.02 | $5.31 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 92.80 | 79.11 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.